Owners
History
2019: The offer of Sobi on purchase of the company for $915 million
On October 1, 2019 it became known that the Swedish pharmaceutical company Swedish Orphan Biovitrum specializing in development of medicines for treatment of rare diseases ("Svedish Orfan Biovitrum", Sobi) announced acquisition of the American Dova Pharmaceuticals ("Dov Pharmasyyutikalz").
Transaction amount can be up to 915 million dollars.
Sobi offers shareholders of Dova 27.50 dollars for an action and 1.50 more dollars if the medicine Doptelet will be approved by FDA for treatment of thrombocytopenia after chemotherapy.
The transaction will allow the Swedish company competing with Roche (Roche), Novo Nordisk ("It is new Nordisk") and Shire (Shayer) to fill up the product portfolio in the field of hematology and to expand presence on the American pharmaceutical market.
The deal is going to be closed in the IV quarter 2019[1].
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |